In one of the most significant consumer-goods mergers of the year, Kimberly-Clark is buying Tylenol maker Kenvue in a ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven ...

The combined company will have a large stable of household brands under one roof, putting Kenvue’s Listerine mouthwash and ...

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive ...

Kenvue is under scrutiny after the Trump administration linked Tylenol to autism. Merger aims for $32 billion in annual revenue and $7 billion operating profit. The deal is expected to close in the ...

The drug has recently been in headlines, but an apparent issue with "defective containers" is connected to this FDA ...